Trevi Therapeutics/$TRVI
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Ticker
$TRVI
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
31
ISIN
US89532M1018
Website
TRVI Metrics
BasicAdvanced
$712M
-
-$0.44
0.62
-
Price and volume
Market cap
$712M
Beta
0.62
52-week high
$7.48
52-week low
$2.36
Average daily volume
2.2M
Financial strength
Current ratio
15.383
Quick ratio
15.106
Long term debt to equity
0.685
Total debt to equity
0.962
Interest coverage (TTM)
-17,029.33%
Profitability
EBITDA (TTM)
-50.939
Effective tax rate (TTM)
0.07%
Management effectiveness
Return on assets (TTM)
-34.41%
Return on equity (TTM)
-55.12%
Valuation
Price to book
6.01
Price to tangible book (TTM)
6.01
Price to free cash flow (TTM)
-15.42
Free cash flow yield (TTM)
-6.49%
Free cash flow per share (TTM)
-38.78%
Growth
Earnings per share change (TTM)
31.48%
3-year earnings per share growth (CAGR)
-29.72%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
Bulls say / Bears say
Oppenheimer increased its price target for Trevi Therapeutics from $12.00 to $20.00, indicating a potential upside of over 200% (etfdailynews.com)
Trevi Therapeutics reported positive topline data from its Phase 2a RIVER trial, showing a 57% placebo-adjusted reduction in 24-hour cough frequency for refractory chronic cough patients (stocktitan.net)
The company has a strong cash position of $107.6 million, providing a financial runway into the second half of 2026, supporting ongoing and future clinical trials (stocktitan.net)
Trevi Therapeutics reported a net loss of $11.4 million in Q4 2024, an increase from $7.8 million in the same quarter of the previous year, indicating rising operational expenses (stocktitan.net)
The company's research and development expenses increased to $9.3 million in Q4 2024 from $6.5 million in Q4 2023, reflecting higher costs associated with clinical trials (stocktitan.net)
Despite positive trial results, Trevi Therapeutics has not yet achieved profitability, which may concern investors looking for immediate returns (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
TRVI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $712M as of July 04, 2025.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of July 04, 2025.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.